Probing the Role of Meso ‐DAP and Lysine for Growth and Pathogenicity of Pseudomonas aeruginosa
MicrobiologyOpen · 2025-12 · 14 (6)
DOI: 10.1002/mbo3.70200 ↗Kurz gefasst
Fachartikel in der Zeitschrift MicrobiologyOpen, online erschienen am 22.12.2025. Verfasst von Daniel A Hawkins und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Agriculture, Food and Wine, Waite Research Institute, The University of Adelaide, Waite Campus, Glen Osmond, South Australia, Australia. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Lysine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, British Society for Antimicrobial Chemotherapy.
Abstract (Originalsprache)
Antibiotic‐resistant bacteria represent a major global challenge as increasing infections become recalcitrant to standard treatments. A lack of novel therapeutics entering the market in the past 30 years further exacerbates this issue and highlights the importance of identifying and validating novel antibiotic targets. In this study, we explored prospective therapeutic targets by examining two metabolites in the lysine biosynthesis pathway, meso ‐diaminopimelate (DAP) and lysine, within the critically listed pathogen Pseudomonas aeruginosa . These metabolites are involved in bacterial cell wall and protein synthesis; therefore, enzymes present in this pathway represent potential targets for novel therapeutics. To elucidate the validity of these targets, we generated for the first time, gene deletion mutants of the P. aeruginosa DHDPR‐ and DAPDC‐encoding genes using a two‐step allelic exchange method. Both the mutants resulted in a lethal phenotype that could be rescued by supplementation with meso ‐DAP and/or lysine. We subsequently characterized the mutants' pathogenicity in a Galleria mellonella infection model. The DHDPR mutant was unable to provide a lethal infection in this model. Given the importance of these metabolites to membrane and cell wall synthesis, we investigated membrane permeability utilizing a fluorescent probe assay and transmission electron microscopy. Due to their increased membrane permeability, these mutants exhibited greater sensitivity to antibiotics commonly used against Pseudomonas infections. Overall, this study highlights that targeting the lysine biosynthesis pathway could enhance bacterial susceptibility to existing antibiotics, supporting its development as an adjuvant strategy to potentiate current treatments and extend their clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Agriculture, Food and Wine, Waite Research Institute, The University of Adelaide, Waite Campus, Glen Osmond, South Australia, Australia.
- Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.
- Antimicrobial Discovery, Development and Diagnostics (AD3), United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, UK.
ORCID-Profile: Tatiana P Soares da Costa
Förderung
- Australian Research Council
- British Society for Antimicrobial Chemotherapy
Zitieren
APA
Hawkins, D. A., Impey, R. E., Hind, C. K., Sutton, J. M., & Soares da Costa, T. P. (2025). Probing the Role of Meso ‐DAP and Lysine for Growth and Pathogenicity of Pseudomonas aeruginosa. MicrobiologyOpen, 14(6). https://doi.org/10.1002/mbo3.70200
Vancouver
Hawkins DA, Impey RE, Hind CK, Sutton JM, Soares da Costa TP. Probing the Role of Meso ‐DAP and Lysine for Growth and Pathogenicity of Pseudomonas aeruginosa. MicrobiologyOpen. 2025;14(6). doi:10.1002/mbo3.70200
BibTeX
@article{Hawkins2025,
author = {Hawkins, Daniel A and Impey, Rachael E and Hind, Charlotte K and Sutton, J Mark and Soares da Costa, Tatiana P},
title = {Probing the Role of Meso ‐DAP and Lysine for Growth and Pathogenicity of Pseudomonas aeruginosa},
journal = {MicrobiologyOpen},
year = {2025},
volume = {14},
number = {6},
doi = {10.1002/mbo3.70200}
}
EUVIMED